Hologic, Inc. HOLX
Verdict: Hold. Fair value $68.27 against a price of $74.75 on 6 Jan 2026, 9% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. Net Income has shown significant volatility, dropping from $1.30B in 2022 to $0.46B in 2023, before....
Main risks
- Significant Revenue & Profit Decline: Revenue, Net Income, and FCF have fallen sharply from a 2022 peak, indicating a cyclical downturn or the end of a one-time tailwind (likely COVID-related diagnostics). The 3-year revenue CAGR is negative.
- Margin Contraction: Net margin has compressed significantly from 26.7% in 2022 to 13.9% in the latest period, signaling a deterioration in profitability and pricing power post-peak.
- Dependence on Proxies: The lack of historical balance sheet data and reported EBIT necessitates using multiple proxies for key metrics like ROIC and ROIIC, which reduces the confidence in long-term trend analysis.
- Intense competitive environment
- Valuation prices in optimistic scenario (limited margin for error)